Replies

“ wrote:
There are many ivermectin studies that are peer reviewed.
Here’s one of the latest ones:

https://www.jiac-j.com/action/showPdf?pii=S1341-321X%2821%2900360-3

How many more do you need? I have them.”
————————————————————————————————————————

Thank you for your comment.

I could probably use a few more of these because they seem to ECHO What I’ve been saying the whole time. Yet the Q and anti-everything crowd don’t seem to notice.

From the Link Source:

“ Ivermectin is a drug that has been used to treat parasitic infections such as onchocerciasis and lymphatic filariasis throughout the world for more than 30 years, with more than 3.7 billion doses dispensed in Africa and Central and South America to control tropical diseases [5]. Iver- mectin shows in vitro activity against a broad range of viruses, including not only HIV, dengue, influenza, and Zika virus but also SARS-CoV-2 [6]. Clinical research by Rajter et al. [7] found that ivermectin treat- ment was associated with lower mortality in 280 COVID-19 patients in a propensity score-matching study. Contrastingly, in a randomized clin- ical trial of 400 patients with mild COVID-19, ivermectin administration did not decrease the time to resolution of symptoms within 21 days [8]. Thus, the effects of ivermectin are controversial, and there are few clinical data on intubated COVID-19 patients in the intensive care unit (ICU).”

(((((Oh looky there, just like David Chase has been saying……”MILD CASES”.))))

Again, from the Link:

“ This study has some limitations. An imbalance in the patients’ age between the treatment groups remained after weighting. The mutant variants may be different with time, but we could not identify this. Additional well-designed studies are needed to provide further eluci- dation. Second, we propose that the intestinal effect of ivermectin might influence COVID-19 infection, and thus, evaluation of intestinal viral load could be a next target to confirm this supposition.
5. Conclusions
The administration of ivermectin improved GI complications and VFD in ventilated patients with COVID-19. The beneficial influence of ivermectin on the intestines may improve outcome in these patients. Further research is needed to investigate the mechanism and effects of ivermectin treatment.”

((((Same words David Chase uses……amazing! Studies have had “LIMITATIONS”,
“We’ll designed studies are needed”
The word “May” pops up throughout……Odd, I use the word “May”.
“Further research is needed”
Where oh where have we heard that before?? Oh, yeah, from ME!))))

Also, here’s a bonus that you apparently missed from the Link:

This is a Japanese Study for Gastro Intestinal effects of Covid-19.
But, they cite Dexamethasone (a Steroid) and Remdesivir!
Why is that interesting?
Apparently this large group of researchers MISSED THE MEMO from one of the nutty Blogs that Remdesivir causes Renal Failure.

“ The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/ COVID-19) pandemic is an emergency situation throughout the world.
As treatment, dexamethasone has been used as an effective anti- inflammatory drug [1], but dexamethasone weakens host immunity [2]. Remdesivir, an antiviral drug, is a nucleoside analogue prodrug used for various viral infections and decreases the time to clinical improvement in adults with severe COVID-19 [3]. However, there are limited data in patients with mechanical ventilation [4].

If you believe this Link that you posted, then you also believe what I’ve been saying the whole time yet I get condemned for it.

Ivermectin can be used for mild cases of Covid.
Beyond that it has its limits like any drug.
Ivermectin may (there’s that word again) reduce symptoms in mild and even moderate cases of SARS.

More research is needed.

Thanks again for the Link.